9267 Genky DrugStares Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

9267

TSE Prime

Genky DrugStares Co.,Ltd.

3,075

JPY

-50

(-1.60%)

Dec 23, 3:30 pm JST

19.63

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

3,085

Dec 23, 3:24 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jun, 2021	142,376	6,294	6,601	4,831	159.2	12.50	Jul 27, 2021	J-GAAP
Jun, 2022	154,639	5,675	6,087	4,420	145.6	12.50	Jul 26, 2022	J-GAAP
Jun, 2023	169,059	6,709	7,079	4,764	156.9	12.50	Jul 24, 2023	J-GAAP
Jun, 2024	184,860	9,015	9,268	6,324	208.2	12.75	Jul 29, 2024	J-GAAP
Jun, 2025 Guidance	202,000	10,000	10,220	7,000	230.3	13	Jul 29, 2024	J-GAAP
YoY	+9.3%	+10.9%	+10.3%	+10.7%	+10.6%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Jun, 2020	Jul 19, 2019	115,000	4,050	4,350	3,000	12.5	J-GAAP
	Jan 22, 2020	117,000	3,000	3,300	2,100	12.5	J-GAAP
	Jul 20, 2020	123,603	4,341	4,566	2,755	12.5	J-GAAP
Results	Jul 27, 2020	123,603	4,341	4,566	2,755	12.5	J-GAAP
Jun, 2021	Jul 27, 2020	Available in future release
	Oct 20, 2020
	Jan 18, 2021
Results	Jul 27, 2021
Jun, 2022	Jul 27, 2021
Results	Jul 26, 2022
Jun, 2023	Jul 26, 2022
	Jul 20, 2023
Results	Jul 24, 2023
Jun, 2024	Jul 24, 2023
	Jan 23, 2024
	Apr 25, 2024
	Jul 23, 2024
Results	Jul 29, 2024
Jun, 2025	Jul 29, 2024	202,000	10,000	10,220	7,000	13*	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jun, 2000	6,242	+19.3	Available in future release
Jun, 2001	8,372	+34.1
Jun, 2002	10,405	+24.3
Jun, 2003	13,234	+27.2
Jun, 2004	16,027	+21.1
Jun, 2005	20,747	+29.5
Jun, 2006	24,436	+17.8
Jun, 2007	28,860	+18.1
Jun, 2008	32,728	+13.4
Jun, 2009	36,925	+12.8
Jun, 2010	41,247	+11.7
Jun, 2011	51,516	+24.9
Jun, 2012	56,700	+10.1
Jun, 2013	54,656	-3.6
Jun, 2014	57,949	+6.0
Jun, 2015	63,143	+9.0
Jun, 2016	73,495	+16.4
Jun, 2017	83,399	+13.5
Jun, 2018	94,869	+13.8
Jun, 2019	103,897	+9.5
Jun, 2020	123,603	+19.0
Jun, 2021	142,376	+15.2
Jun, 2022	154,639	+8.6
Jun, 2023	169,059	+9.3
Jun, 2024	184,860	+9.3
Jun, 2025 Guidance	202,000	+9.3	10,000	+10.9	10,220	+10.3	230.3	+10.6

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Jun, 2023	169,059	6,709	3.97	12.41	4.69	1.67	156.9
Jun, 2024	184,860	9,015	4.88	14.51	5.75	1.68	208.2
Jun, 2025 Guidance	202,000	10,000	4.95	14.59	5.96	1.72	230.3

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	184,860	9,015	9,268	6,324	208.2
Fiscal Year	Jun, 2024	Jun, 2024	Jun, 2024	Jun, 2024	Jun, 2024

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2021	76,241	2,921	3,126	2,132	70.3	6.25	Jan 25, 2022	J-GAAP
Jul - Dec, 2022	83,874	3,364	3,561	2,271	74.8	6.25	Jan 31, 2023	J-GAAP
Jul - Dec, 2023	91,967	4,387	4,495	3,087	101.7	6.25	Jan 29, 2024	J-GAAP
Jul - Dec, 2024 Guidance	100,000	5,000	5,110	3,500	115.2	6.50	Jul 29, 2024	J-GAAP
YoY	+8.7%	+14.0%	+13.7%	+13.4%	+13.3%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2021	Jul 27, 2021	76,800	3,100	3,250	2,260	6.25	J-GAAP
Results	Jan 25, 2022	76,241	2,921	3,126	2,132	6.25	J-GAAP
Dec, 2022	Jul 26, 2022	Available in future release
Results	Jan 31, 2023
Dec, 2023	Jul 24, 2023
	Jan 23, 2024
Results	Jan 29, 2024
Dec, 2024	Jul 29, 2024	100,000	5,000	5,110	3,500	6.5*	J-GAAP

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Jun, 2022	5,675	-4,512	6,076	-10,588	2,037	5,438	5.60	J-GAAP
Jun, 2023	6,709	-963	8,773	-9,736	854	5,329	5.03	J-GAAP
Jun, 2024	9,015	2,625	13,256	-10,631	-2,058	5,896	5.17	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jul - Sep, 2022	42,613	1,584	1,688	1,102	36.3	47.4	Oct 24, 2022	J-GAAP
Jul - Sep, 2023	46,871	2,015	2,089	1,444	47.6	46.5	Oct 30, 2023	J-GAAP
Jul - Sep, 2024	50,050	2,272	2,300	1,584	52.1	45.0	Oct 28, 2024	J-GAAP
YoY	+6.8%	+12.8%	+10.1%	+9.7%	+9.6%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	41,261	1,780	1,873	1,169	38.5	4.3	Jan 31, 2023	J-GAAP
Jan - Mar, 2023	40,331	1,394	1,488	1,042	34.3	3.5	Apr 24, 2023	J-GAAP
Apr - Jun, 2023	44,854	1,951	2,030	1,451	47.8	4.3	Jul 24, 2023	J-GAAP
Jul - Sep, 2023	46,871	2,015	2,089	1,444	47.6	4.3	Oct 30, 2023	J-GAAP
Oct - Dec, 2023	45,096	2,372	2,406	1,643	54.1	5.3	Jan 29, 2024	J-GAAP
Jan - Mar, 2024	44,620	2,107	2,193	1,369	45.1	4.7	Apr 25, 2024	J-GAAP
Apr - Jun, 2024	48,273	2,521	2,580	1,868	61.5	5.2	Jul 29, 2024	J-GAAP
Jul - Sep, 2024	50,050	2,272	2,300	1,584	52.1	4.5	Oct 28, 2024	J-GAAP
YoY	+6.8%	+12.8%	+10.1%	+9.7%	+9.6%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	27,825	+9.8	Available in future release
Jan - Mar, 2020	29,872	+22.1
Apr - Jun, 2020	37,401	+36.0
Jul - Sep, 2020	35,075	+23.0
Oct - Dec, 2020	34,042	+22.3
Jan - Mar, 2021	34,333	+14.9
Apr - Jun, 2021	38,926	+4.1
Jul - Sep, 2021	39,118	+11.5
Oct - Dec, 2021	37,123	+9.1
Jan - Mar, 2022	37,525	+9.3
Apr - Jun, 2022	40,873	+5.0
Jul - Sep, 2022	42,613	+8.9
Oct - Dec, 2022	41,261	+11.1
Jan - Mar, 2023	40,331	+7.5
Apr - Jun, 2023	44,854	+9.7
Jul - Sep, 2023	46,871	+10.0
Oct - Dec, 2023	45,096	+9.3
Jan - Mar, 2024	44,620	+10.6
Apr - Jun, 2024	48,273	+7.6
Jul - Sep, 2024	50,050	+6.8	2,272	+12.8	2,300	+10.1	52.1	+9.5

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	50,050	2,521	2,580	1,868	61.5
Fiscal Year	Sep, 2024	Jun, 2024	Jun, 2024	Jun, 2024	Jun, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Jun, 2022	2,383.41	37.3	97,118	36,186	29,531	0.86	Jul 26, 2022	J-GAAP
Jun, 2023	2,674.34	38.3	105,912	40,607	33,917	0.80	Jul 24, 2023	J-GAAP
Jun, 2024	3,065.62	40.9	113,939	46,572	39,862	0.65	Jul 29, 2024	J-GAAP
Jul - Sep, 2024	ー	40.8	117,471	47,974	41,249	0.72	Oct 28, 2024	J-GAAP

Genky DrugStares Co.,Ltd.(9267) Financial Results